Ricky

“Wondering if you could share anything about Mach V growth in the quarter. and previously you've had some comments around positive regulatory feedback and the potential for this to replace traditional viral clearance studies.”

“So, you gave some color on the Unity confirmed launch and adoption and the 50% opt-in for the eligible results. So while it's still early in the launch, do you think that that's already starting to drive share gains in NIPT?”

“So 64% revenue growth and 60% volume growth in the U.S. is really impressive. Could you provide some additional color on where you're seeing the most growth here, maybe which types of customers, and how much of this is from existing SOFIA DVM applications and how much of it is from MSK applications?”

“So following the launch of Genome Next, do you have any updates on your outlook for the rare disease ramp within AMBRI? And, you know, in the letter you'd mentioned, you're expecting this to pick up in the second half.”

“Wondering what you saw with respect to market share changes in the women's health market in 2025 and then what your guidance and some of the volume comments you made for women's health is assuming with respect to further market share gains?”